French drugmaker Sanofi (SASY.PA) plans to spend 1 to 2 billion euros ($1.4-2.7 billion) each year on acquisitions, its chief executive, Chris Viehbacher, told Le Figaro newspaper. Since taking the helm five years ago, Viehbacher has sought to refill Sanofi's drug pipeline, spending 24 billion euros on acquisitions - including on the takeover of U.S. biotech firm Genzyme - to offset the loss of patents on top-selling drugs.
Help employers find you! Check out all the jobs and post your resume.
